Chimerix (Chimerix) EBIT per Share : $-1.05 (TTM As of Mar. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Chimerix EBIT per Share?

Chimerix's EBIT per Share for the three months ended in Mar. 2024 was $-0.27. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.05.

During the past 3 years, the average EBIT per Share Growth Rate was -13.60% per year. During the past 5 years, the average EBIT per Share Growth Rate was 6.10% per year. During the past 10 years, the average EBIT per Share Growth Rate was 9.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Chimerix's EBIT per Share or its related term are showing as below:

CMRX' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -108.6 Med: 10.2 Max: 22.4
Current: -13.6

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Chimerix was 22.40% per year. The lowest was -108.60% per year. And the median was 10.20% per year.

CMRX's 3-Year EBIT Growth Rate is ranked worse than
69.43% of 1305 companies
in the Biotechnology industry
Industry Median: 3.6 vs CMRX: -13.60

Chimerix's EBIT for the three months ended in Mar. 2024 was $-24.39 Mil.

Chimerix EBIT per Share Historical Data

The historical data trend for Chimerix's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chimerix EBIT per Share Chart

Chimerix Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-0.92

-0.72

-1.07

-0.68

-1.05

Chimerix Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial															-0.27	-0.24	-0.30	-0.23	-0.27

Chimerix EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Chimerix's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-93.065	/	88.604
=	-1.05

Chimerix's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-24.39	/	89.259
=	-0.27

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.05

Chimerix (NAS:CMRX) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Chimerix EBIT per Share Related Terms

Thank you for viewing the detailed overview of Chimerix's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Chimerix (Chimerix) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chimerix Inc (NAS:CMRX) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

CXF:Germany CXF:Germany

Address

2505 Meridian Parkway, Suite 100, Durham, NC, USA, 27713

Website

https://www.chimerix.com

Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through license agreements and a federal contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA) for research and advanced development of drugs to treat various human diseases. The company operates only in one business segment namely pharmaceuticals.

Executives

Fred A Middleton	director	400 SOUTH EL CAMINO REAL STE 1200, SAN MATEO CA 94402-1708
David Jakeman	officer: Principal Accounting Officer	C/O CHIMERIX, INC.,, 2505 MERIDIAN PARKWAY, SUITE 100, DURHAM NC 27713
Michael A. Sherman	director, officer: Chief Executive Officer	3000 KENT AVE STE A1-100, WEST LAFAYETTE IN 47906
Martha J Demski	director	7770 REGENTS ROAD SUITE 113-505, SAN DIEGO CA 92122
Robert J. Meyer	director	2505 MERIDIAN PARKWAY, C/O CHIMERIX, INC, SUITE 100, DURHAM NC 27713
Michael T. Andriole	officer: Chief Business Officer	C/O ENDOCYTE, INC., 3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906
Cantex Pharmaceuticals, Inc.	10 percent owner	1792 BELL TOWER LANE, SUITE 222, WESTON FL 33326
Victoria Vakiener	director	C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Allen S. Melemed	officer: Chief Medical Officer	C/O CHIMERIX, INC., 2505 MERIDIAN PARKWAY, SUITE 100, DURHAM NC 27713
Pratik S Multani	director	C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121
William Garrett Nichols	officer: Chief Medical Officer	C/O CANDEL THERAPEUTICS, INC., 117 KENDRICK ST SUITE 450, NEEDHAM MA 02494
Michael Albert Alrutz	officer: Principal Executive Officer	2530 MERIDIAN PARKWAY, 2ND FLOOR, DURHAM NC 27713
M Michelle Berrey	officer: Chief Medical Officer	303A COLLEGE ROAD EAST, PRINCETON NJ 08450
Ernest Mario	director	20 FAIRMOUNT AVENUE, P.O. BOX 445, CHATHAM NJ 07928
Ed Greissing	director	2505 MERIDIAN PARKWAY, C/O CHIMERIX, INC, SUITE 100, DURHAM NC 27713